Company Filing History:
9 out of 142 
1 out of 84 
1 out of 297 Years Active: 1997-2006
Title: Gary M Studnicka: Innovator in Immunotoxin Development
Introduction
Gary M Studnicka is a prominent inventor based in Santa Monica, CA (US). He has made significant contributions to the field of immunotoxins, particularly through his innovative patents. With a total of 11 patents to his name, Studnicka has established himself as a key figure in the development of therapeutic agents aimed at treating various diseases.
Latest Patents
One of his latest patents focuses on immunotoxins comprising ribosome-inactivating proteins (RIPs). This invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins and their analogs, which have a cysteine available for disulfide bonding to targeting molecules. The vectors comprising these polynucleotides and the host cells transformed with the vectors are also included in the patent. The RIPs and their analogs are particularly suited for use as components of cytotoxic therapeutic agents, including gene fusion products and immunoconjugates. These immunotoxins can selectively eliminate any cell type targeted by the RIP component, making them valuable for treating diseases such as autoimmune disorders, cancer, and graft-versus-host disease.
Career Highlights
Throughout his career, Gary M Studnicka has worked with notable companies, including Xoma Corporation and Xoma Technology Ltd. His work in these organizations has contributed to advancements in the field of immunology and therapeutic development.
Collaborations
Studnicka has collaborated with esteemed colleagues, including Marc D Better and Stephen Fitzhugh Carroll. These partnerships have further enhanced his research and innovation in the field.
Conclusion
Gary M Studnicka's contributions to the field of immunotoxins and his innovative patents highlight his role as a leading inventor. His work continues to impact the development of targeted therapeutic agents for various diseases.